Mokari Atabak sold $3.5M of CORT
Mokari Atabak (Chief Financial Officer) sold 40,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $87.71 ($86.78–$89.43, $3.51M total) across 4 trades on 2026-07-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale amount ($3.51M) and remaining holdings (16,130 shares) may slightly influence sentiment, but the 10b5-1 plan reduces interpretive weight.
Market read
Traders may monitor for clustering of insider activity, but this specific disclosure adds limited new fundamental information.
What to watch
The article does not disclose whether other insiders sold/bought around the same time, nor does it provide post-sale performance context beyond remaining shares.
Background
The article is an SEC Form 4 insider transaction for Corcept Therapeutics, reported by the CFO.
Ticker impact
Corcept Therapeutics CFO Mokari Atabak sold about $3.51M of CORT shares via an open-market sale under a 10b5-1 plan.
Likely minimal price impact; any effect is more sentiment-driven than fundamental.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating, regulatory, or financial guidance.
Market effects
No clear sector read-through; this is company-specific insider trading data.
None.
None.
Counterpoint
10b5-1 sales are often scheduled and not necessarily bearish; the sale may reflect diversification or liquidity needs rather than outlook.
Key entities
- issuerCorcept Therapeutics
Company whose shares were sold by its CFO under a 10b5-1 plan.
- insiderMokari Atabak
Chief Financial Officer who executed the open-market sale.
